Diamyd Medical's principal owner transfers half of his holdings in Diamyd Medical to his children

Diamyd Medical announces that its principal owner Anders Essen-Möller has notified the Swedish Financial Supervisory Authority of the sale of 4,500,000 Diamyd Medical shares in the form of gifts. Essen-Möller’s five children each receive 400,000 Class A shares and 500,000 Class B shares.

The transaction corresponds to approximately half of Essen-Möller's holdings, which after the transaction amount to 4,556,263 shares, of which 1,187,000 shares in an endowment policy. After the transaction, Essen-Möller's shareholding in Diamyd Medical corresponds to an equity interest of approximately 4.4% and a voting interest of approximately 8.4%.

“As a soon-to-be 81-year-old, I see it as responsible to start some de-escalation and one step is to divide my shareholding in Diamyd to my five children, says Anders Essen-Möller, Board member of Diamyd Medical. “I think the timing of this, which is hard to choose, is still pretty good right now. I am confident that our therapeutic diabetes vaccine will be the game-changer we all hope. The evidence that Diamyd treatment produces an extremely important effect in individuals with type-1 diabetes, and who carry the DR3-DQ2 gene, is cementing.”

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. DIAGNODE-3, a confirmatory Phase III trial is on-going. A vaccine manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on May 9, 2022, 08.00 CET.


  PDF version